Zai Lab Limited logo
Zai Lab Limited ZLAB
$ 18.58 6.29%

Quarterly report 2025-Q3
added 11-06-2025

report update icon

Zai Lab Limited Financial Statements 2011-2025 | ZLAB

Annual Financial Statements Zai Lab Limited

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

34.2 B 21.8 B 38.5 B 50.9 B 115 B 3.32 B 1.42 B 541 M - - - - - -

Shares

989 M 966 M 958 M 930 M 777 M 64.4 M 52.6 M 21.8 M - - - - - -

Historical Prices

34.6 22.6 40.2 54.7 148 55 28.8 22.1 - - - - - -

Net Income

-257 M -335 M -443 M -704 M -269 M -195 M -139 M -50.4 M -37.5 M -18 M - - - -

Revenue

399 M 267 M 215 M 144 M 49 M 13 M 129 K - - - - - - -

Cost of Revenue

147 M 95.8 M 74 M 52.2 M 16.7 M 3.75 M 43 K - - - - - - -

Gross Profit

- - - - - 9.24 M 85.9 K - - - - - - -

Operating Income

-282 M -367 M -404 M -700 M -302 M -203 M -142 M -51.4 M -38.5 M -16.3 M - - - -

Interest Expense

2.25 M 7.01 M 3.11 M -10.2 M 181 K 293 K 40 K 530 K - - - - - -

EBITDA

-270 M -358 M -396 M -694 M -297 M -199 M -140 M -51 M -36.4 M -14.2 M - - - -

Operating Expenses

- - - - - 212 M 142 M - - - - - - -

General and Administrative Expenses

299 M 282 M 259 M 219 M 111 M 70.2 M - 12 M 6.38 M 2.76 M - - - -

All numbers in USD currency

Quarterly Income Statement Zai Lab Limited

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

1.1 B 1.09 B 1.08 B 1.08 B 982 M 976 M 973 M 972 M 969 M 965 M 961 M 960 M 959 M 958 M 955 M 955 M 950 M 930 M 884 M 87.8 M 75.4 M 74.7 M 73 M 68.2 M 67.8 M - - 58 M - - - 49.9 M - - - 9.66 M - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-36 M -40.7 M -48.4 M - -41.7 M -80.3 M -53.5 M - -69.2 M -121 M -49.1 M - -161 M -138 M -82.4 M -212 M -96.4 M -163 M -233 M -76.5 M -63.7 M -80.6 M -48 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

116 M 110 M 106 M - 102 M 101 M 87.1 M - 69.2 M 68.9 M 62.8 M - 57.5 M 48.2 M 46.7 M 44 M 43.1 M 36.9 M 20.1 M 15.1 M 14.7 M 11 M 8.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

46.8 M 43 M 38.5 M - 36.6 M 35.1 M 33.6 M - 25.5 M 23.8 M 21.3 M - 20 M 17.4 M 15.6 M - 12.2 M 10.9 M 7.5 M - 4.93 M 2.9 M 2.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-48.8 M -54.9 M -56.3 M - -67.9 M -76.1 M -70.3 M - -83.6 M -89.5 M -69.5 M - -129 M -98.7 M -79.8 M -219 M -83.2 M -171 M -227 M -95.3 M -76.3 M -84 M -46.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

-508 K 3.75 M -197 K - 3.44 M -8.94 M 9.36 M - 394 K -1.4 M 1.23 M - 3.96 M -5.5 M -4.88 M - -13.6 M 7.41 M -6.23 M - 43 K 55 K 59 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-46.4 M -52.6 M -52.9 M - -65.8 M -73.9 M -67.3 M - -81.8 M -87.7 M -66.9 M - -126 M -97 M -77.8 M -219 M -78.6 M -168 M -226 M -95.3 M -73 M -81.9 M -45.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

70.1 M 71 M 63.4 M - 67.2 M 79.7 M 69.2 M - 68.6 M 67.9 M 62.5 M - 66.6 M 63.4 M 57 M - 59 M 54.4 M 35.8 M - 27.9 M 23.8 M 18.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Zai Lab Limited ZLAB
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Zai Lab Limited plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.79 2.35 % $ 795 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.04 4.83 % $ 235 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 0.93 -8.81 % $ 257 K usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 212.81 1.71 % $ 5 B danmarkDanmark
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
BioVie BioVie
BIVI
$ 1.27 -3.05 % $ 1.88 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.1 0.16 % $ 7.46 B australiaAustralia
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.37 2.06 % $ 814 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 26.83 0.94 % $ 1.73 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.03 0.95 % $ 27.2 B germanyGermany
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.81 1.36 % $ 1.3 B usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 83.59 1.95 % $ 8.63 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.48 0.96 % $ 139 M usaUSA
CorMedix CorMedix
CRMD
$ 12.19 1.75 % $ 621 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.18 -25.03 % $ 392 M israelIsrael
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 591.15 0.02 % $ 44.8 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.53 -0.39 % $ 15.9 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 92.45 0.34 % $ 96.9 B britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA